Iliad Neurosciences, Inc., based in Plymouth Meeting, PA., was launched in 2013 to develop commercially viable biomarkers and diagnostics to identify and treat neurological diseases. Its’ first diagnostic product, termed FRAT™, screens for antibodies to the Folate Receptor A and is targeted towards children with Autism Spectrum Disorders, and those that have other neurological deficiencies. The company continues to pursue its research in Folate Receptor Antibodies and Folate Metabolism and the relation of each in various neurodevelopment disorders. The management team is led by Boas Gonen, MD who has over 20 years of experience in R&D with Wyeth Pharmaceuticals, Steven J. Adelman who is a seasoned pharmaceutical executive with over 20 years experience in drug discovery and therapeutic development, and Steve Tsetsekos who has over 20 years of experience in finance, private equity and venture capital including investing and developing biotechnology companies. Iliad Neurosciences Inc. believes that its’ emerging science will lead to revolutionary discoveries in the diagnostic and therapeutic
areas of Autism, Schizophrenia, Cerebral Folate Deficiency, Neural Tube Defects, Depression, Chronic Fatigue Syndrome,
Multiple Sclerosis and Parkinson’s.
